Journal Home
Search for

Volume 120, Issue 2, Pages 255-262 (August 2007)


View previous. 21 of 61 View next.

Probiotics for the prevention or treatment of allergic diseases

Susan L. Prescott, MD, PhDaCorresponding Author Informationemail address, Bengt Björkstén, MD, PhDb

Received 14 March 2007; received in revised form 20 April 2007; accepted 23 April 2007. published online 04 June 2007.

This review addresses the effects of probiotic bacteria on immune development and the role in the treatment and prevention of allergic disease. Although there is a sound theoretical basis for anticipating benefits, there are currently insufficient data to recommend probiotics as a part of standard therapy in any allergic conditions. Furthermore, although there have been several studies to show a benefit in prevention of atopic eczema, other studies have failed to support this. None of the studies has shown any clear preventive effect on sensitization, nor any allergic disease other than eczema. The term “probiotic” is often used loosely to include bacterial strains with little documented immunomodulatory capacity or controlled studies to support the claims. It is not known whether effects in experimental systems have any clinical relevance. Finally, very little is known about this large, complex internal ecosystem. Explanations for the varied results between studies include host factors (including genetic differences in microbial responses and allergic predisposition) and other environmental factors, such as general microbial burden, individual microbiota, diet (including consumption of prebiotic substances), and treatment with antibiotics. As more studies are completed, these factors are likely to make robust meta-analyses problematic to perform.

Perth, Australia, and Stockholm, Sweden

a From the School of Paediatrics and Child Health Research, University of Western Australia

b National Institute of Environmental Medicine/Immunology, Division of Physiology, Karolinska Institutet, Stockholm

Corresponding Author InformationReprint requests: Susan L. Prescott, MD, PhD, School of Paediatrics and Child Health Research, University of Western Australia, PO Box D184, Princess Margaret Hospital, Perth WA 6001, Australia.

 Disclosure of potential conflict of interest: S. L. Prescott has received grant support from the National Health and Medical Research Council of Australia and from Probiomics. B. Björkstén has consulting arrangements with and has received grant support from Biogaia.

PII: S0091-6749(07)00865-2

doi:10.1016/j.jaci.2007.04.027


View previous. 21 of 61 View next.